Danaher (DHR) Stock

$209.92 -0.09 (-0.04%)

Market Cap: $151.62B | NYSE

Danaher Chart

Company Profile

Price: $209.92

Market Cap: $151.62B

Exchange: NYSE

CEO: Mr. Rainer M. Blair

Sector: Healthcare

Industry: Medical - Diagnostics & Research

Employees: 61.00K

Headquarters: Washington, DC

Website: Danaher

Business Summary

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

Danaher News

Danaher Analysts Cut Their Forecasts After Downbeat Earnings

Danaher Corporation DHR reported weaker-than-expected fourth-quarter earnings on Wednesday.

Danaher Q4 Earnings Miss Estimates, Life Sciences Sales Rise Y/Y

DHR's fourth-quarter sales increase 2.1% year over year, benefiting from the solid performance of its Life Sciences and Biotechnology segments.

Danaher (DHR) Reports Q4 Earnings: What Key Metrics Have to Say

The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Danaher Corporation (DHR) Q4 2024 Earnings Call Transcript

Danaher (DHR) Lags Q4 Earnings Estimates

Danaher (DHR) came out with quarterly earnings of $2.14 per share, missing the Zacks Consensus Estimate of $2.17 per share. This compares to earnings of $2.09 per share a year ago.

Danaher misses quarterly profit estimates on weak biotech demand

Danaher on Wednesday missed Wall Street estimates for fourth-quarter profit due to soft demand for tools and services used in drug development by its biotech and pharmaceutical clients.

Danaher Reports Fourth Quarter and Full Year 2024 Results

WASHINGTON , Jan. 29, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2024. All results in this release reflect only continuing operations unless otherwise noted.

MARUY vs. DHR: Which Stock Should Value Investors Buy Now?

Investors with an interest in Diversified Operations stocks have likely encountered both Marubeni Corp. (MARUY) and Danaher (DHR). But which of these two stocks is more attractive to value investors?

Danaher Gears Up to Post Q4 Earnings: What Lies Ahead for the Stock?

DHR's Q4 results are likely to be ailed by weakness in the Biotechnology and Life Sciences segments.

Danaher (DHR) Earnings Expected to Grow: Should You Buy?

Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications

FARGO, N.D.--(BUSINESS WIRE)--Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications.

Danaher: Transition Year Recap

Danaher faced a disappointing 2024, despite beating Q3 expectations, due to unaltered full-year guidance and a significant asset writedown. The company executed a $4.5 billion share buyback, with an additional 20 million shares authorized, reflecting confidence in long-term growth. Danaher's ROIC appears low due to heavy R&D and capex investments, but this expands its competitive moat and deters new entrants.

The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems

In a challenging market marked by uncertainty, building a resilient portfolio is key to long-term financial stability and peace of mind. Sleep-well-at-night, or SWAN, stocks are key. These reliable dividend stocks thrive despite volatility, offering steady income and solid growth in uncertain times. Building a balanced portfolio of 10 carefully selected SWAN stocks ensures consistent returns. This strategy offers peace of mind, regardless of market fluctuations.

Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research

New, Fully Automated, High-Throughput RUO Assays offered on Beckman Coulter Immunoassay Analyzers BREA, Calif. , Jan. 15, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a global leader in advanced diagnostics, today announced availability of new Research Use Only (RUO) blood-based biomarker immunoassays designed to advance neurodegenerative disease research.

Danaher Corporation (DHR) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

Danaher Corporation (NYSE:DHR ) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2024 2:15 PM ET Company Participants Rainer Blair - President and Chief Executive Officer Conference Call Participants Rachel Vatnsdal - J.P.

Danaher CEO to Comment on Financial Performance

WASHINGTON , Jan. 13, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2024 performance in a presentation at the J.P.

Using SA's Stock Screener: Sell 6 Overvalued Blue Chips, With Stagnating Growth

Seeking Alpha's Quant Valuation and Growth Grades identify 6 blue-chip stocks with extremely high valuations matched against limited operating growth potential. Costco, Cencora, West Pharmaceutical Services, Danaher, Madison Square Garden Sports, and Estée Lauder appear to be at risk of disappointing investors in 2025. Weakening technical performance vs. the S&P 500 is part of the bearish sell/avoid equation for each since summer.

Danaher Announces Investment Partnership in Innovaccer Inc.

Partnership seeks to improve patient outcomes and experience through novel digital and diagnostic solutions. Investment aligns with Danaher's mission to accelerate the transition to precision medicine with AI-enabled diagnostics.

Danaher to Present at J.P. Morgan Healthcare Conference

WASHINGTON , Jan. 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that its President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P.

Danaher: A Wide-Moat Gem I Cannot Buy Enough Of

Danaher boasts a wide-moat business model with mission-critical products and recurring revenue streams, ensuring a durable competitive advantage and long-term growth potential. The company's disciplined M&A strategy and integration capabilities have driven significant value creation, supported by strong secular healthcare trends and a focus on innovation. Despite a modest 0.5% dividend yield, Danaher's 12.4% five-year CAGR and low payout ratio offer substantial growth potential for total return investors.

Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?

Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Danaher Schedules Fourth Quarter 2024 Earnings Conference Call

WASHINGTON , Jan. 2, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2024 on Wednesday, January 29, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour.

3 of the Best Companies to Own in 2025 and Beyond

#Morningstar  #BestStockstoInvestIn #StockInvesting These companies have durable competitive advantages and generate reliable cash flows. 00:00 Introduction 00:46 Danaher DHR 01:36 Paychex PAYX 02:17 Equifax EFX I'm Susan Dziubinski with Morningstar.

Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value

Concentrate on a select few high-conviction stocks across different sectors to avoid "diworsification" and maximize returns, inspired by Charlie Munger and Warren Buffett. Utilize Joel Greenblatt's "Magic Formula" and James O'Shaughnessy's methodologies to screen stocks based on earnings yield and return on total capital. Exclude overly regulated sectors like Utilities, Financials, and REITs to focus on sectors with higher growth potential and less regulatory constraints.

Danaher Announces Quarterly Dividend

WASHINGTON , Dec. 10, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on January 31, 2025 to holders of record on December 27, 2024. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health.

Here's Why You Should Avoid Investing in Danaher Stock Right Now

DHR experiences weakness in its operations due to softness in the Life Sciences segment. Rising expenses are added concerns.

Danaher: A Resilient And Solid Company With Growth Potential

Danaher has maintained a net earning margin above 15% since 2017. In 2024 Q3, the company had a 36.36% liabilities-to-assets ratio, the lowest level since 2017. Danaher's largest customers have reduced their excess of COVID-19-related products. So, Danaher expects a further boost in its sales.

Danaher Corporation (DHR) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)

Danaher Corporation (NYSE:DHR ) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 3:25 PM ET Company Participants Rainer Blair - President and CEO Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar Great. Thanks, everyone, for joining us this afternoon.

Danaher to Present at Evercore ISI HealthCONx Conference

WASHINGTON , Nov. 26, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conference in Coral Gables, Florida on Wednesday, December 4, 2024 at 3:25 p.m.

Revving Up: 2 Underperforming Dividend Giants Ready To Outshine

Two high-quality dividend stocks are finally positioned for a strong rebound. After a period of underperformance, their growth potential is back in focus. These companies have adapted well to recent challenges, enhancing their strategies to boost shareholder returns. Their fundamentals are solid and undervalued. With robust dividends and renewed growth trajectories, both stocks stand ready to outperform. Ideal picks for investors seeking stability and upside potential.

Danaher Earnings

This section highlights Danaher's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.

Next Earnings Date

Date: April 22, 2025

Time: Before Market

Est. EPS: $1.66

Status: Unconfirmed

Last Earnings Results

Date: January 29, 2025

EPS: $2.14

Est. EPS: $2.14

Revenue: $6.54B

Earnings Call Transcripts

Transcript	Quarter	Year	Date	Estimated EPS	Actual EPS
Read Transcript	Q4	2024	2025-01-29	$2.14	$2.14
Read Transcript	Q3	2024	2024-10-22	$1.57	$1.71
Read Transcript	Q2	2024	2024-07-23	$1.57	$1.72
Read Transcript	Q1	2024	2024-05-14	N/A	N/A
Read Transcript	Q4	2023	2024-01-30	$1.90	$2.09
Read Transcript	Q3	2023	2023-10-24	$1.83	$2.02
Read Transcript	Q2	2023	2023-07-25	$2.00	$2.05
Read Transcript	Q1	2023	2023-04-25	$2.25	$2.36

Financial Statements

Access annual & quarterly financial statements for Danaher, including income statements, balance sheets, and cash flow statements..

Breakdown	December 31, 2024	December 31, 2023	December 31, 2022	December 31, 2021	December 31, 2020
Revenue	$23.88B	$23.89B	$31.47B	$29.45B	$22.28B
Cost of Revenue	$9.67B	$9.86B	$12.52B	$11.50B	$9.81B
Gross Profit	$14.21B	$14.03B	$18.95B	$17.95B	$12.47B
Gross Profit Ratio	59.50%	58.74%	60.21%	60.95%	55.98%
Research and Development Expenses	$1.58B	$1.50B	$1.75B	$1.74B	$1.35B
General and Administrative Expenses	$-	$-	$-	$-	$-
Selling and Marketing Expenses	$-	$-	$-	$-	$-
Selling General and Administrative Expenses	$7.76B	$7.25B	$8.52B	$8.20B	$6.90B
Other Expenses	$-	$77.00M	$-226.00M	$547.00M	$39.00M
Operating Expenses	$9.34B	$8.83B	$10.26B	$10.49B	$8.24B
Cost and Expenses	$19.01B	$18.69B	$22.78B	$21.99B	$18.05B
Interest Income	$117.00M	$303.00M	$41.00M	$11.00M	$71.00M
Interest Expense	$-278.00M	$286.00M	$211.00M	$238.00M	$275.00M
Depreciation and Amortization	$-	$2.17B	$2.13B	$2.17B	$1.77B
EBITDA	$4.86B	$7.50B	$9.71B	$10.01B	$6.59B
EBITDA Ratio	20.37%	31.39%	34.08%	34.29%	27.45%
Operating Income	$4.86B	$5.20B	$8.69B	$7.46B	$4.23B
Operating Income Ratio	20.37%	21.77%	27.61%	25.35%	18.99%
Total Other Income Expenses Net	$-217.00M	$-158.00M	$-390.00M	$133.00M	$264.00M
Income Before Tax	$4.65B	$5.04B	$8.29B	$7.60B	$4.50B
Income Before Tax Ratio	19.46%	21.11%	26.35%	25.80%	20.17%
Income Tax Expense	$747.00M	$823.00M	$1.08B	$1.25B	$849.00M
Net Income	$3.90B	$4.76B	$7.21B	$6.43B	$3.65B
Net Income Ratio	16.33%	19.94%	22.91%	21.84%	16.36%
EPS	$5.33	$6.44	$9.80	$8.77	$4.97
EPS Diluted	$5.29	$6.38	$9.64	$8.61	$4.89
Weighted Average Shares Outstanding	731.00M	736.50M	725.10M	714.60M	706.20M
Weighted Average Shares Outstanding Diluted	737.20M	743.10M	737.10M	736.80M	718.70M
SEC Filing	Source	Source	Source	Source	Source

Income Statement Charts

Breakdown	December 31, 2024	September 27, 2024	June 28, 2024	March 29, 2024	December 31, 2023	September 29, 2023	June 30, 2023	March 31, 2023	December 31, 2022	September 30, 2022	July 01, 2022	April 01, 2022	December 31, 2021	October 01, 2021	July 02, 2021	April 02, 2021	December 31, 2020	October 02, 2020	July 03, 2020	April 03, 2020
Revenue	$6.54B	$5.80B	$5.74B	$5.80B	$2.69B	$6.87B	$7.16B	$7.17B	$8.37B	$7.66B	$7.75B	$7.69B	$8.15B	$7.23B	$7.22B	$6.86B	$6.76B	$5.88B	$5.30B	$4.34B
Cost of Revenue	$2.65B	$2.40B	$2.31B	$2.31B	$1.07B	$2.87B	$3.12B	$2.80B	$3.43B	$3.08B	$3.03B	$2.98B	$3.21B	$2.87B	$2.82B	$2.60B	$2.81B	$2.66B	$2.44B	$1.90B
Gross Profit	$3.89B	$3.40B	$3.43B	$3.49B	$1.62B	$4.00B	$4.04B	$4.37B	$4.94B	$4.58B	$4.72B	$4.71B	$4.94B	$4.36B	$4.40B	$4.25B	$3.95B	$3.23B	$2.85B	$2.44B
Gross Profit Ratio	59.50%	58.66%	59.69%	60.16%	60.27%	58.20%	56.46%	60.97%	59.02%	59.82%	60.91%	61.20%	60.67%	60.30%	60.92%	62.02%	58.49%	54.83%	53.85%	56.25%
Research and Development Expenses	$442.00M	$383.00M	$391.00M	$368.00M	$239.00M	$417.00M	$418.00M	$429.00M	$453.00M	$420.00M	$431.00M	$441.00M	$495.00M	$441.00M	$426.00M	$380.00M	$396.00M	$342.60M	$322.60M	$287.00M
General and Administrative Expenses	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-
Selling and Marketing Expenses	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-
Selling General and Administrative Expenses	$2.02B	$2.06B	$1.87B	$1.81B	$766.00M	$2.15B	$2.19B	$2.15B	$2.19B	$2.15B	$2.08B	$2.09B	$2.29B	$2.06B	$1.97B	$1.88B	$1.96B	$1.80B	$1.69B	$1.46B
Other Expenses	$-	$-	$-	$1.00M	$1.00M	$1.00M	$-29.00M	$2.00M	$-68.00M	$13.00M	$11.00M	$-20.00M	$82.00M	$137.00M	$97.00M	$140.00M	$35.00M	$6.40M	$-700.00K	$-1.50M
Operating Expenses	$2.46B	$2.44B	$2.26B	$2.17B	$1.00B	$2.56B	$2.61B	$2.58B	$2.64B	$2.57B	$2.52B	$2.53B	$2.79B	$3.05B	$2.39B	$2.26B	$2.35B	$2.14B	$2.01B	$1.75B
Cost and Expenses	$5.11B	$4.84B	$4.58B	$4.48B	$2.08B	$5.43B	$5.73B	$5.37B	$6.07B	$5.65B	$5.55B	$5.52B	$5.99B	$5.92B	$5.21B	$4.86B	$5.16B	$4.80B	$4.45B	$3.65B
Interest Income	$14.00M	$4.00M	$39.00M	$60.00M	$117.00M	$79.00M	$59.00M	$48.00M	$29.00M	$9.00M	$2.00M	$1.00M	$1.00M	$3.00M	$3.00M	$4.00M	$4.00M	$4.20M	$1.00M	$62.50M
Interest Expense	$-61.00M	$87.00M	$65.00M	$65.00M	$78.00M	$73.00M	$67.00M	$68.00M	$64.00M	$42.00M	$51.00M	$54.00M	$56.00M	$62.00M	$62.00M	$58.00M	$72.00M	$76.70M	$78.60M	$47.40M
Depreciation and Amortization	$-	$591.00M	$580.00M	$586.00M	$493.00M	$554.00M	$562.00M	$557.00M	$565.00M	$540.00M	$552.00M	$565.00M	$587.00M	$554.00M	$525.00M	$502.00M	$508.60M	$492.00M	$478.00M	$297.00M
EBITDA	$1.43B	$1.66B	$1.75B	$1.92B	$1.83B	$2.02B	$2.02B	$2.42B	$2.83B	$2.57B	$2.78B	$2.74B	$2.81B	$2.44B	$2.54B	$2.64B	$2.12B	$1.82B	$1.32B	$1.01B
EBITDA Ratio	21.80%	28.54%	30.44%	32.75%	45.64%	30.15%	20.39%	33.50%	26.97%	33.63%	35.74%	28.00%	27.45%	27.71%	36.44%	38.54%	24.26%	27.02%	24.96%	24.32%
Operating Income	$1.43B	$958.00M	$1.17B	$1.31B	$541.00M	$1.44B	$897.00M	$1.79B	$1.69B	$2.02B	$2.21B	$1.59B	$2.15B	$1.31B	$2.00B	$2.00B	$1.60B	$1.09B	$844.60M	$697.50M
Operating Income Ratio	21.80%	16.52%	20.34%	22.64%	20.09%	20.92%	12.53%	25.03%	20.22%	26.30%	28.45%	20.66%	26.44%	18.11%	27.78%	29.12%	23.68%	18.49%	15.94%	16.06%
Total Other Income Expenses Net	$-110.00M	$19.00M	$-85.00M	$-41.00M	$-84.00M	$-41.00M	$229.00M	$4.00M	$-103.00M	$-84.00M	$-136.00M	$-73.00M	$-69.00M	$78.00M	$38.00M	$86.00M	$-59.00M	$-66.10M	$376.30M	$13.60M
Income Before Tax	$1.31B	$977.00M	$1.08B	$1.27B	$457.00M	$1.40B	$1.39B	$1.80B	$2.19B	$1.93B	$2.07B	$2.10B	$2.08B	$1.39B	$2.04B	$2.08B	$1.54B	$1.02B	$1.22B	$711.10M
Income Before Tax Ratio	20.11%	16.85%	18.86%	21.93%	16.97%	20.33%	19.45%	25.09%	26.20%	25.20%	26.69%	27.30%	25.59%	19.19%	28.30%	30.37%	22.81%	17.36%	23.05%	16.37%
Income Tax Expense	$229.00M	$159.00M	$176.00M	$183.00M	$-79.00M	$268.00M	$286.00M	$348.00M	$-39.00M	$359.00M	$389.00M	$374.00M	$297.00M	$229.00M	$344.00M	$381.00M	$301.00M	$138.00M	$293.60M	$116.00M
Net Income	$1.09B	$818.00M	$907.00M	$1.09B	$1.08B	$1.13B	$1.11B	$1.45B	$2.23B	$1.55B	$1.66B	$1.68B	$1.75B	$1.12B	$1.74B	$1.66B	$1.20B	$842.00M	$892.00M	$576.00M
Net Income Ratio	16.61%	14.11%	15.79%	18.77%	40.07%	16.43%	15.45%	20.23%	26.67%	20.24%	21.39%	21.90%	21.44%	15.45%	24.16%	24.22%	17.74%	14.31%	16.84%	13.26%
EPS	$1.50	$1.13	$1.23	$1.47	$1.46	$1.53	$1.50	$1.96	$3.03	$2.13	$2.28	$2.35	$2.44	$1.56	$2.44	$2.33	$1.69	$1.18	$1.27	$0.83
EPS Diluted	$1.49	$1.12	$1.22	$1.45	$1.45	$1.51	$1.49	$1.94	$2.96	$2.10	$2.25	$2.28	$2.39	$1.54	$2.40	$2.29	$1.66	$1.16	$1.24	$0.81
Weighted Average Shares Outstanding	722.70M	723.00M	737.60M	740.60M	739.80M	739.40M	737.30M	729.40M	728.90M	728.50M	726.70M	716.30M	715.60M	715.10M	714.50M	713.20M	711.60M	710.90M	705.10M	697.20M
Weighted Average Shares Outstanding Diluted	728.20M	729.40M	742.40M	748.60M	746.10M	745.90M	744.70M	737.20M	745.70M	737.40M	736.00M	737.70M	738.40M	727.00M	736.00M	735.10M	724.50M	724.30M	718.20M	707.90M
SEC Filing	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source	Source

Annual Balance Sheet

Annual
Quarterly

Breakdown	December 31, 2023	December 31, 2022	December 31, 2021	December 31, 2020	December 31, 2019
Cash and Cash Equivalents	$5.86B	$6.00B	$2.59B	$6.04B	$19.91B
Short Term Investments	$-	$-	$-	$-	$-
Cash and Short Term Investments	$5.86B	$6.00B	$2.59B	$6.04B	$19.91B
Net Receivables	$3.92B	$4.18B	$4.63B	$4.04B	$3.19B
Inventory	$2.59B	$3.11B	$2.77B	$2.29B	$1.63B
Other Current Assets	$1.56B	$2.94B	$1.66B	$1.43B	$865.00M
Total Current Assets	$13.94B	$15.88B	$11.65B	$13.80B	$25.60B
Property Plant Equipment Net	$4.55B	$3.96B	$3.79B	$3.26B	$2.30B
Goodwill	$41.61B	$39.75B	$41.18B	$35.42B	$22.71B
Intangible Assets	$20.75B	$20.30B	$22.84B	$21.28B	$9.75B
Goodwill and Intangible Assets	$62.35B	$60.05B	$64.03B	$56.70B	$32.46B
Long Term Investments	$-	$11.00M	$20.00M	$27.00M	$33.70M
Tax Assets	$-	$-11.00M	$-20.00M	$-27.00M	$-33.70M
Other Non-Current Assets	$3.64B	$4.46B	$3.72B	$2.40B	$1.72B
Total Non-Current Assets	$70.55B	$68.47B	$71.54B	$62.36B	$36.48B
Other Assets	$-	$-	$-	$-	$-
Total Assets	$84.49B	$84.35B	$83.18B	$76.16B	$62.08B
Account Payables	$1.77B	$1.86B	$2.57B	$2.05B	$1.51B
Short Term Debt	$1.88B	$758.00M	$215.00M	$200.00M	$370.00M
Tax Payables	$582.00M	$691.00M	$707.00M	$552.00M	$356.50M
Deferred Revenue	$1.47B	$1.65B	$1.61B	$1.21B	$687.80M
Other Current Liabilities	$2.59B	$5.08B	$3.04B	$3.39B	$2.00B
Total Current Liabilities	$8.27B	$8.39B	$8.14B	$7.40B	$4.93B
Long Term Debt	$17.66B	$19.86B	$23.06B	$21.98B	$22.16B
Deferred Revenue Non-Current	$249.00M	$235.00M	$213.00M	$205.00M	$118.10M
Deferred Tax Liabilities Non-Current	$-	$-	$-213.00M	$-205.00M	$-118.10M
Other Non-Current Liabilities	$4.81B	$6.01B	$6.60B	$6.80B	$4.59B
Total Non-Current Liabilities	$22.72B	$25.87B	$29.87B	$28.98B	$26.87B
Other Liabilities	$-	$-	$-	$-	$-
Total Liabilities	$31.00B	$34.26B	$38.01B	$36.38B	$31.80B
Preferred Stock	$-	$1.67B	$3.27B	$3.27B	$1.60B
Common Stock	$9.00M	$9.00M	$9.00M	$9.00M	$8.40M
Retained Earnings	$41.07B	$39.20B	$32.83B	$27.16B	$24.17B
Accumulated Other Comprehensive Income Loss	$-1.75B	$-2.87B	$-1.03B	$-368.00M	$-3.07B
Other Total Stockholders Equity	$14.15B	$12.07B	$10.09B	$9.70B	$7.56B
Total Stockholders Equity	$53.49B	$50.08B	$45.17B	$39.77B	$30.27B
Total Equity	$53.49B	$50.09B	$45.18B	$39.78B	$30.28B
Total Liabilities and Stockholders Equity	$84.49B	$84.35B	$83.18B	$76.16B	$62.08B
Minority Interest	$4.00M	$8.00M	$10.00M	$11.00M	$11.30M
Total Liabilities and Total Equity	$84.49B	$84.35B	$83.18B	$76.16B	$62.08B
Total Investments	$5.00M	$11.00M	$20.00M	$27.00M	$33.70M
Total Debt	$19.54B	$19.68B	$22.18B	$21.20B	$21.73B
Net Debt	$13.67B	$13.68B	$19.59B	$15.17B	$1.82B

Balance Sheet Charts

Breakdown	December 31, 2024	September 27, 2024	June 28, 2024	March 29, 2024	December 31, 2023	September 29, 2023	June 30, 2023	March 31, 2023	December 31, 2022	September 30, 2022	July 01, 2022	April 01, 2022	December 31, 2021	October 01, 2021	July 02, 2021	April 02, 2021	December 31, 2020	October 02, 2020	July 03, 2020	April 03, 2020
Cash and Cash Equivalents	$2.08B	$2.63B	$2.37B	$7.03B	$5.86B	$12.28B	$8.57B	$7.38B	$6.00B	$5.15B	$3.98B	$3.72B	$2.59B	$2.55B	$7.32B	$6.33B	$6.04B	$5.69B	$5.54B	$4.37B
Short Term Investments	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-
Cash and Short Term Investments	$2.08B	$2.63B	$2.37B	$7.03B	$5.86B	$12.28B	$8.57B	$7.38B	$6.00B	$5.15B	$3.98B	$3.72B	$2.59B	$2.55B	$7.32B	$6.33B	$6.04B	$5.69B	$5.54B	$4.37B
Net Receivables	$3.54B	$3.51B	$3.30B	$3.38B	$3.92B	$4.20B	$4.20B	$4.31B	$5.88B	$4.41B	$4.53B	$4.41B	$4.63B	$4.19B	$4.10B	$3.95B	$4.04B	$3.50B	$3.38B	$3.43B
Inventory	$2.33B	$2.68B	$2.67B	$2.65B	$2.59B	$3.02B	$3.18B	$3.38B	$3.11B	$3.24B	$3.26B	$3.07B	$2.77B	$2.74B	$2.55B	$2.42B	$2.29B	$2.42B	$2.59B	$2.58B
Other Current Assets	$1.55B	$1.25B	$1.27B	$1.32B	$1.56B	$1.70B	$1.50B	$1.46B	$2.66B	$2.83B	$2.83B	$2.86B	$1.66B	$1.29B	$1.42B	$1.31B	$1.43B	$936.10M	$833.20M	$766.60M
Total Current Assets	$9.50B	$10.06B	$9.61B	$14.37B	$13.94B	$21.20B	$17.46B	$16.53B	$15.88B	$14.25B	$13.23B	$12.67B	$11.65B	$10.78B	$15.39B	$14.01B	$13.80B	$12.54B	$12.34B	$11.14B
Property Plant Equipment Net	$4.99B	$4.84B	$5.74B	$5.66B	$4.55B	$4.30B	$4.18B	$4.07B	$3.96B	$3.72B	$3.79B	$3.81B	$3.79B	$3.64B	$3.41B	$3.27B	$3.26B	$3.05B	$2.97B	$2.99B
Goodwill	$40.50B	$42.17B	$40.80B	$40.85B	$41.61B	$39.16B	$39.58B	$39.86B	$39.75B	$38.25B	$39.28B	$40.66B	$41.18B	$41.24B	$35.59B	$34.88B	$35.42B	$34.27B	$33.23B	$33.73B
Intangible Assets	$18.57B	$19.85B	$19.55B	$19.89B	$20.75B	$18.79B	$19.32B	$19.98B	$20.30B	$19.96B	$20.91B	$22.15B	$22.84B	$23.38B	$20.52B	$20.39B	$21.28B	$20.85B	$20.44B	$18.51B
Goodwill and Intangible Assets	$59.06B	$62.03B	$60.35B	$60.73B	$62.35B	$57.94B	$58.89B	$59.83B	$60.05B	$58.22B	$60.18B	$62.81B	$64.03B	$64.61B	$56.11B	$55.27B	$56.70B	$55.12B	$53.67B	$52.24B
Long Term Investments	$-	$1.70B	$476.00M	$370.00M	$5.00M	$4.00M	$7.00M	$9.00M	$11.00M	$13.00M	$15.00M	$17.00M	$20.00M	$21.00M	$23.00M	$25.00M	$27.00M	$29.60M	$31.30M	$35.40M
Tax Assets	$-	$-	$-	$-	$-5.00M	$-4.00M	$-7.00M	$-9.00M	$-11.00M	$-13.00M	$-15.00M	$-17.00M	$-20.00M	$-21.00M	$-23.00M	$-25.00M	$-27.00M	$-29.60M	$-31.30M	$-35.40M
Other Non-Current Assets	$3.99B	$1.98B	$2.38B	$2.26B	$3.64B	$4.29B	$4.37B	$4.61B	$4.46B	$4.85B	$4.60B	$4.10B	$3.72B	$3.47B	$3.12B	$2.88B	$2.40B	$2.17B	$2.28B	$2.56B
Total Non-Current Assets	$68.05B	$70.56B	$68.95B	$69.03B	$70.55B	$66.53B	$67.44B	$68.51B	$68.47B	$66.78B	$68.58B	$70.72B	$71.54B	$71.72B	$62.63B	$61.41B	$62.36B	$60.35B	$58.92B	$57.79B
Other Assets	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-
Total Assets	$77.54B	$80.61B	$78.56B	$83.40B	$84.49B	$87.73B	$84.90B	$85.04B	$84.35B	$81.03B	$81.81B	$83.39B	$83.18B	$82.50B	$78.03B	$75.43B	$76.16B	$72.89B	$71.27B	$68.93B
Account Payables	$1.75B	$1.60B	$1.65B	$1.68B	$1.77B	$1.89B	$1.96B	$2.08B	$2.30B	$2.19B	$2.42B	$2.36B	$2.57B	$2.13B	$1.97B	$1.99B	$2.05B	$1.68B	$1.60B	$1.75B
Short Term Debt	$505.00M	$1.20B	$701.00M	$1.75B	$1.88B	$2.55B	$1.59B	$1.57B	$758.00M	$705.00M	$10.00M	$10.00M	$215.00M	$7.00M	$23.00M	$10.00M	$200.00M	$19.70M	$17.20M	$3.23B
Tax Payables	$-	$-	$-	$-	$582.00M	$-	$-	$-	$691.00M	$-	$-	$-	$707.00M	$-	$-	$-	$552.00M	$-	$-	$-
Deferred Revenue	$-	$-	$-	$-	$1.47B	$-	$-	$-	$1.65B	$-	$-	$-	$1.61B	$-	$-	$-	$1.21B	$-	$-	$-
Other Current Liabilities	$4.54B	$4.54B	$4.36B	$4.35B	$2.59B	$4.93B	$4.86B	$5.08B	$4.64B	$5.11B	$5.13B	$5.18B	$3.04B	$5.12B	$4.83B	$4.83B	$3.39B	$4.34B	$3.98B	$3.48B
Total Current Liabilities	$6.80B	$7.34B	$6.70B	$7.78B	$8.27B	$9.37B	$8.40B	$8.73B	$8.39B	$8.00B	$7.56B	$7.55B	$8.14B	$7.26B	$6.83B	$6.82B	$7.40B	$6.04B	$5.60B	$8.47B
Long Term Debt	$15.50B	$16.32B	$17.51B	$17.52B	$17.66B	$20.61B	$19.39B	$19.36B	$19.95B	$19.54B	$21.15B	$22.87B	$23.06B	$24.62B	$21.41B	$21.25B	$21.98B	$22.74B	$23.26B	$23.60B
Deferred Revenue Non-Current	$-	$-	$-	$-	$249.00M	$-	$-	$-	$235.00M	$-	$-	$-	$213.00M	$-	$-	$-	$205.00M	$-	$-	$-
Deferred Tax Liabilities Non-Current	$-	$-	$-	$-	$4.59B	$-	$-	$-	$-	$-	$-	$-	$-213.00M	$-	$-	$-	$-205.00M	$-	$-	$-
Other Non-Current Liabilities	$5.70B	$5.65B	$4.44B	$4.66B	$4.81B	$5.34B	$5.39B	$5.46B	$5.92B	$6.49B	$6.50B	$6.62B	$6.60B	$7.16B	$7.03B	$6.93B	$6.80B	$6.14B	$6.13B	$5.80B
Total Non-Current Liabilities	$21.20B	$21.97B	$21.95B	$22.18B	$22.72B	$25.95B	$24.77B	$24.82B	$25.87B	$26.04B	$27.65B	$29.48B	$29.87B	$31.78B	$28.44B	$28.17B	$28.98B	$28.88B	$29.40B	$29.40B
Other Liabilities	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-
Total Liabilities	$28.00B	$29.31B	$28.65B	$29.95B	$31.00B	$35.32B	$33.18B	$33.55B	$34.26B	$34.04B	$35.20B	$37.03B	$38.01B	$39.04B	$35.26B	$35.00B	$36.38B	$34.92B	$35.00B	$37.86B
Preferred Stock	$-	$-	$-	$-	$-	$-	$-	$1.67B	$1.67B	$1.67B	$1.67B	$3.27B	$3.27B	$3.27B	$3.27B	$3.27B	$3.27B	$3.27B	$3.27B	$1.60B
Common Stock	$9.00M	$9.00M	$9.00M	$9.00M	$9.00M	$9.00M	$9.00M	$9.00M	$9.00M	$9.00M	$9.00M	$9.00M	$9.00M	$9.00M	$9.00M	$9.00M	$9.00M	$8.50M	$8.50M	$8.40M
Retained Earnings	$44.19B	$43.30B	$42.67B	$41.96B	$41.07B	$42.27B	$41.34B	$40.44B	$39.20B	$37.18B	$35.81B	$34.33B	$32.83B	$31.23B	$30.26B	$28.67B	$27.16B	$26.09B	$25.37B	$24.61B
Accumulated Other Comprehensive Income Loss	$-3.22B	$-1.31B	$-2.59B	$-2.74B	$-1.75B	$-3.96B	$-3.58B	$-2.77B	$-2.87B	$-3.85B	$-2.75B	$-1.38B	$-1.03B	$-1.06B	$-675.00M	$-1.32B	$-368.00M	$-1.02B	$-1.86B	$-2.79B
Other Total Stockholders Equity	$8.56B	$9.30B	$9.81B	$14.21B	$14.15B	$14.09B	$13.94B	$12.13B	$12.07B	$11.98B	$11.85B	$10.12B	$10.09B	$10.00B	$9.89B	$9.79B	$9.70B	$9.62B	$9.48B	$7.63B
Total Stockholders Equity	$49.54B	$51.30B	$49.90B	$53.44B	$53.49B	$52.41B	$51.72B	$51.48B	$50.08B	$46.98B	$46.59B	$46.36B	$45.17B	$43.45B	$42.76B	$40.42B	$39.77B	$37.96B	$36.26B	$31.06B
Total Equity	$49.55B	$51.30B	$49.90B	$53.45B	$53.49B	$52.41B	$51.72B	$51.49B	$50.09B	$46.99B	$46.60B	$46.36B	$45.18B	$43.46B	$42.77B	$40.43B	$39.78B	$37.97B	$36.27B	$31.07B
Total Liabilities and Stockholders Equity	$77.54B	$80.61B	$78.56B	$83.40B	$84.49B	$87.73B	$84.90B	$85.04B	$84.35B	$81.03B	$81.81B	$83.39B	$83.18B	$82.50B	$78.03B	$75.43B	$76.16B	$72.89B	$71.27B	$68.93B
Minority Interest	$7.00M	$6.00M	$5.00M	$5.00M	$4.00M	$8.00M	$8.00M	$8.00M	$8.00M	$8.00M	$7.00M	$6.00M	$10.00M	$10.00M	$10.00M	$11.00M	$11.00M	$11.50M	$11.20M	$11.30M
Total Liabilities and Total Equity	$77.54B	$80.61B	$78.56B	$83.40B	$84.49B	$87.73B	$84.90B	$85.04B	$84.35B	$81.03B	$81.81B	$83.39B	$83.18B	$82.50B	$78.03B	$75.43B	$76.16B	$72.89B	$71.27B	$68.93B
Total Investments	$-	$1.70B	$476.00M	$370.00M	$5.00M	$4.00M	$7.00M	$9.00M	$11.00M	$13.00M	$15.00M	$17.00M	$20.00M	$21.00M	$23.00M	$25.00M	$27.00M	$29.60M	$31.30M	$35.40M
Total Debt	$16.00B	$17.52B	$18.21B	$19.26B	$19.54B	$22.06B	$19.88B	$19.83B	$19.68B	$19.25B	$20.06B	$21.78B	$22.18B	$23.60B	$20.42B	$20.28B	$21.20B	$21.83B	$22.39B	$25.97B
Net Debt	$13.93B	$14.90B	$15.84B	$12.23B	$13.67B	$9.78B	$11.30B	$12.45B	$13.68B	$14.10B	$16.08B	$18.06B	$19.59B	$21.05B	$13.10B	$13.95B	$15.17B	$16.14B	$16.85B	$21.60B

Annual Cash Flow

Annual
Quarterly

Breakdown	December 31, 2024	December 31, 2023	December 31, 2022	December 31, 2021	December 31, 2020
Net Income	$3.90B	$4.22B	$7.21B	$6.35B	$3.65B
Depreciation and Amortization	$2.35B	$2.17B	$2.22B	$2.17B	$1.77B
Deferred Income Tax	$-483.00M	$-	$-559.00M	$-318.00M	$-462.00M
Stock Based Compensation	$288.00M	$306.00M	$295.00M	$184.00M	$187.00M
Change in Working Capital	$-	$-393.00M	$-1.52B	$-658.00M	$605.00M
Accounts Receivables	$331.00M	$322.00M	$-477.00M	$-611.00M	$-264.00M
Inventory	$147.00M	$185.00M	$-486.00M	$-502.00M	$-123.00M
Accounts Payables	$19.00M	$-149.00M	$5.00M	$549.00M	$227.00M
Other Working Capital	$-	$-751.00M	$-561.00M	$-94.00M	$765.00M
Other Non Cash Items	$632.00M	$864.00M	$830.00M	$601.00M	$457.00M
Net Cash Provided by Operating Activities	$6.69B	$7.16B	$8.52B	$8.36B	$6.21B
Investments in Property Plant and Equipment	$-1.39B	$-1.38B	$-1.15B	$-1.29B	$-791.00M
Acquisitions Net	$-	$-5.61B	$-637.00M	$-10.94B	$-20.14B
Purchases of Investments	$-331.00M	$-172.00M	$-523.00M	$-934.00M	$-342.00M
Sales Maturities of Investments	$253.00M	$61.00M	$18.00M	$126.00M	$13.00M
Other Investing Activities	$-511.00M	$23.00M	$60.00M	$50.00M	$26.00M
Net Cash Used for Investing Activities	$-1.98B	$-7.08B	$-2.23B	$-12.99B	$-21.24B
Debt Repayment	$-	$-1.63B	$-1.69B	$1.97B	$-1.90B
Common Stock Issued	$-	$68.00M	$31.00M	$86.00M	$1.88B
Common Stock Repurchased	$-5.98B	$-	$-	$-	$-
Dividends Paid	$-768.00M	$-821.00M	$-818.00M	$-742.00M	$-615.00M
Other Financing Activities	$-7.62B	$2.11B	$-95.00M	$-16.00M	$1.64B
Net Cash Used Provided by Financing Activities	$-8.38B	$-273.00M	$-2.57B	$1.29B	$1.01B
Effect of Forex Changes on Cash	$-108.00M	$59.00M	$-306.00M	$-115.00M	$148.00M
Net Change in Cash	$-3.79B	$-131.00M	$3.41B	$-3.45B	$-13.88B
Cash at End of Period	$2.08B	$5.86B	$6.00B	$2.59B	$6.04B
Cash at Beginning of Period	$5.86B	$6.00B	$2.59B	$6.04B	$19.91B
Operating Cash Flow	$6.69B	$7.16B	$8.52B	$8.36B	$6.21B
Capital Expenditure	$-1.39B	$-1.38B	$-1.15B	$-1.29B	$-791.00M
Free Cash Flow	$5.30B	$5.78B	$7.37B	$7.06B	$5.42B

Cash Flow Charts

Breakdown	December 31, 2024	September 27, 2024	June 28, 2024	March 29, 2024	December 31, 2023	September 29, 2023	June 30, 2023	March 31, 2023	December 31, 2022	September 30, 2022	July 01, 2022	April 01, 2022	December 31, 2021	October 01, 2021	July 02, 2021	April 02, 2021	December 31, 2020	October 02, 2020	July 03, 2020	April 03, 2020
Net Income	$-	$818.00M	$907.00M	$1.09B	$536.00M	$1.13B	$1.11B	$1.45B	$2.23B	$1.57B	$1.68B	$1.73B	$1.79B	$1.16B	$1.70B	$1.70B	$1.24B	$883.50M	$927.30M	$595.10M
Depreciation and Amortization	$-	$591.00M	$580.00M	$586.00M	$493.00M	$554.00M	$562.00M	$557.00M	$565.00M	$540.00M	$552.00M	$565.00M	$587.00M	$554.00M	$525.00M	$502.00M	$508.60M	$491.50M	$477.10M	$297.80M
Deferred Income Tax	$-	$-	$-	$-324.00M	$-1.20B	$-	$-	$-	$-559.00M	$-	$-	$-	$-229.00M	$-	$-	$-	$518.00M	$-	$-	$-
Stock Based Compensation	$-	$84.00M	$87.00M	$60.00M	$26.00M	$114.00M	$96.00M	$70.00M	$66.00M	$89.00M	$101.00M	$80.00M	$59.00M	$52.00M	$53.00M	$54.00M	$49.90M	$45.00M	$47.00M	$45.00M
Change in Working Capital	$-	$-99.00M	$-216.00M	$-57.00M	$-242.00M	$-151.00M	$117.00M	$-117.00M	$-407.00M	$-255.00M	$-431.00M	$-426.00M	$-139.00M	$-161.00M	$-44.00M	$-314.00M	$383.30M	$-114.80M	$448.60M	$-112.10M
Accounts Receivables	$-	$-	$74.00M	$516.00M	$-387.00M	$-56.00M	$134.00M	$631.00M	$-343.00M	$11.00M	$-225.00M	$80.00M	$-459.00M	$-81.00M	$-130.00M	$59.00M	$-475.40M	$-62.90M	$92.70M	$181.60M
Inventory	$-	$35.00M	$-34.00M	$-118.00M	$210.00M	$103.00M	$129.00M	$-257.00M	$243.00M	$-61.00M	$-237.00M	$-431.00M	$-64.00M	$-146.00M	$-121.00M	$-171.00M	$120.70M	$-173.30M	$105.20M	$-175.60M
Accounts Payables	$-	$-82.00M	$-30.00M	$-74.00M	$250.00M	$-36.00M	$-135.00M	$-228.00M	$185.00M	$-169.00M	$120.00M	$-131.00M	$449.00M	$170.00M	$-32.00M	$-38.00M	$334.00M	$53.30M	$-170.30M	$10.00M
Other Working Capital	$-	$-52.00M	$-226.00M	$-381.00M	$-315.00M	$-162.00M	$-11.00M	$-263.00M	$-492.00M	$-36.00M	$-89.00M	$56.00M	$-65.00M	$-104.00M	$239.00M	$-164.00M	$404.00M	$68.10M	$421.00M	$-128.10M
Other Non Cash Items	$2.02B	$119.00M	$1.30B	$970.00M	$2.01B	$48.00M	$32.00M	$-22.00M	$644.00M	$64.00M	$98.00M	$24.00M	$267.00M	$431.00M	$-113.00M	$-73.00M	$-478.60M	$417.20M	$-454.60M	$-7.00M
Net Cash Provided by Operating Activities	$2.02B	$1.51B	$1.42B	$1.74B	$1.62B	$1.67B	$1.93B	$1.95B	$2.54B	$2.01B	$2.00B	$1.97B	$2.33B	$2.03B	$2.12B	$1.87B	$2.22B	$1.72B	$1.45B	$819.00M
Investments in Property Plant and Equipment	$-516.00M	$-298.00M	$-287.00M	$-291.00M	$-402.00M	$-365.00M	$-341.00M	$-275.00M	$-329.00M	$-277.00M	$-296.00M	$-250.00M	$-420.00M	$-318.00M	$-305.00M	$-251.00M	$-316.00M	$-187.00M	$-155.00M	$-133.00M
Acquisitions Net	$-	$-502.00M	$-11.00M	$-	$-5.61B	$4.00M	$4.00M	$42.00M	$-333.00M	$-227.00M	$-60.00M	$-17.00M	$-333.00M	$-9.56B	$-646.00M	$-393.00M	$-152.40M	$-66.80M	$808.70M	$-20.73B
Purchases of Investments	$-	$-61.00M	$-74.00M	$-53.00M	$-20.00M	$-8.00M	$-101.00M	$-43.00M	$-169.00M	$-26.00M	$-54.00M	$-274.00M	$-150.00M	$-232.00M	$-132.00M	$-420.00M	$-127.10M	$-87.10M	$-90.50M	$-37.30M
Sales Maturities of Investments	$-	$242.00M	$-	$9.00M	$28.00M	$29.00M	$3.00M	$1.00M	$271.00M	$1.00M	$114.00M	$17.00M	$22.00M	$48.00M	$13.00M	$43.00M	$13.00M	$153.90M	$-718.20M	$20.77B
Other Investing Activities	$-178.00M	$13.00M	$12.00M	$14.00M	$-13.00M	$11.00M	$4.00M	$-29.00M	$-256.00M	$14.00M	$-104.00M	$21.00M	$2.00M	$17.00M	$3.00M	$28.00M	$1.50M	$-142.00M	$694.00M	$-20.73B
Net Cash Used for Investing Activities	$-694.00M	$-606.00M	$-360.00M	$-321.00M	$-6.02B	$-329.00M	$-431.00M	$-304.00M	$-816.00M	$-515.00M	$-400.00M	$-503.00M	$-879.00M	$-10.05B	$-1.07B	$-993.00M	$-581.00M	$-329.00M	$539.00M	$-20.87B
Debt Repayment	$-	$-14.00M	$-1.03B	$68.00M	$-4.22B	$2.60B	$-3.00M	$-4.00M	$-704.00M	$-50.00M	$-944.00M	$10.00M	$-1.15B	$3.48B	$14.00M	$-280.00M	$-1.25B	$-1.21B	$-4.20B	$4.76B
Common Stock Issued	$-	$-	$-	$-1.00M	$102.00M	$55.00M	$30.00M	$-34.00M	$16.00M	$38.00M	$-23.00M	$-46.00M	$23.00M	$38.00M	$-	$-12.00M	$28.30M	$56.00M	$1.79B	$10.30M
Common Stock Repurchased	$-	$-640.00M	$-4.53B	$-	$-	$-	$-	$-	$46.00M	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-	$-
Dividends Paid	$-	$-196.00M	$-200.00M	$-177.00M	$-200.00M	$-199.00M	$-218.00M	$-204.00M	$-203.00M	$-204.00M	$-220.00M	$-191.00M	$-191.00M	$-191.00M	$-191.00M	$-169.00M	$-169.60M	$-162.00M	$-145.00M	$-138.00M
Other Financing Activities	$-	$5.00M	$42.00M	$-24.00M	$2.11B	$39.00M	$13.00M	$-20.00M	$-15.00M	$24.00M	$4.00M	$-93.00M	$-100.00M	$13.00M	$1.00M	$-	$-26.40M	$-1.00M	$1.67B	$-
Net Cash Used Provided by Financing Activities	$-	$-845.00M	$-5.71B	$-133.00M	$-2.25B	$2.44B	$-208.00M	$-262.00M	$-906.00M	$-230.00M	$-1.16B	$-274.00M	$-1.42B	$3.31B	$-139.00M	$-449.00M	$-1.42B	$-1.32B	$-889.00M	$4.63B
Effect of Forex Changes on Cash	$-	$191.00M	$1.00M	$-118.00M	$231.00M	$-84.00M	$-91.00M	$3.00M	$26.00M	$-99.00M	$-173.00M	$-60.00M	$2.00M	$-61.00M	$78.00M	$-134.00M	$127.00M	$74.00M	$76.00M	$-129.00M
Net Change in Cash	$-	$253.00M	$-4.66B	$1.17B	$-6.41B	$3.70B	$1.20B	$1.38B	$845.00M	$1.17B	$267.00M	$1.13B	$34.00M	$-4.77B	$992.00M	$295.00M	$347.00M	$149.00M	$1.17B	$-15.54B
Cash at End of Period	$-	$2.63B	$2.37B	$7.03B	$5.86B	$12.28B	$8.57B	$7.38B	$6.00B	$5.15B	$3.98B	$3.72B	$2.59B	$2.55B	$7.32B	$6.33B	$6.04B	$5.69B	$5.54B	$4.37B
Cash at Beginning of Period	$-	$2.37B	$7.03B	$5.86B	$12.28B	$8.57B	$7.38B	$6.00B	$5.15B	$3.98B	$3.72B	$2.59B	$2.55B	$7.32B	$6.33B	$6.04B	$5.69B	$5.54B	$4.37B	$19.91B
Operating Cash Flow	$2.02B	$1.51B	$1.42B	$1.74B	$1.62B	$1.67B	$1.93B	$1.95B	$2.54B	$2.01B	$2.00B	$1.97B	$2.33B	$2.03B	$2.12B	$1.87B	$2.22B	$1.72B	$1.45B	$819.00M
Capital Expenditure	$-516.00M	$-298.00M	$-287.00M	$-291.00M	$-402.00M	$-365.00M	$-341.00M	$-275.00M	$-329.00M	$-277.00M	$-296.00M	$-250.00M	$-420.00M	$-318.00M	$-305.00M	$-251.00M	$-316.00M	$-187.00M	$-155.00M	$-133.00M
Free Cash Flow	$1.50B	$1.22B	$1.13B	$1.45B	$1.22B	$1.31B	$1.58B	$1.67B	$2.21B	$1.73B	$1.70B	$1.72B	$1.91B	$1.72B	$1.81B	$1.62B	$1.91B	$1.54B	$1.29B	$686.00M

Build your own charts

Danaher Stock Forecast

Analyst ratings, price targets, and earnings estimates for DHR.

DHR Analyst Ratings

Moderate Buy

Buy

Hold

Sell

Based on 23 analysts in the past 3 months

DHR Stock 12 Month Forecast

$262.50

▲ (25.05% Upside)

Highest Price Target

$ (0.0%)

Average Price Target

$262.50 (25.0%)

Lowest Price Target

$ (0.0%)

Based on 2 analysts in the last 3 months

Recent Price Targets

Recommendation Trends

Analyst Estimates

Revenue Estimates

High $25.51B

Average $24.86B

Low $24.69B

18 analysts

Net Income Estimates

High $6.33B

Average $6.16B

Low $5.98B

18 analysts

EPS Estimates

High $8.59

Average $8.21

Low $8.12

16 analysts

Revenue Estimates

High $27.05B

Average $26.67B

Low $26.47B

20 analysts

Net Income Estimates

High $7.10B

Average $6.83B

Low $6.57B

20 analysts

EPS Estimates

High $9.63

Average $9.17

Low $8.91

16 analysts

Revenue Estimates

High $28.83B

Average $28.52B

Low $28.20B

11 analysts

Net Income Estimates

High $7.79B

Average $7.60B

Low $7.41B

11 analysts

EPS Estimates

High $10.57

Average $10.34

Low $10.05

4 analysts

Revenue Estimates

High $31.24B

Average $30.20B

Low $29.93B

4 analysts

Net Income Estimates

High $8.83B

Average $8.45B

Low $8.35B

4 analysts

EPS Estimates

High $11.98

Average $11.46

Low $11.33

3 analysts

Revenue Estimates

High $33.04B

Average $31.94B

Low $31.65B

5 analysts

Net Income Estimates

High $8.78B

Average $8.40B

Low $8.30B

5 analysts

EPS Estimates

High $11.91

Average $11.40

Low $11.26

2 analysts

Latest Price Target Updates

Date	Analyst	Firm	Price Target	Price When Posted	Upside
Jan 15, 2025	Matthew Sykes	Goldman Sachs	$250.00	$237.97	5.1%
Dec 19, 2024	Subbu Nambi	Guggenheim	$275.00	$228.66	20.3%
Oct 31, 2024	Doug Schenkel	Wolfe Research	$285.00	$242.32	17.6%
Oct 23, 2024	Paul Knight	KeyBanc	$310.00	$257.67	20.3%
Oct 23, 2024	Catherine Schulte	Robert W. Baird	$277.00	$261.28	6.0%
Oct 23, 2024	Puneet Souda	Leerink Partners	$275.00	$261.28	5.3%
Oct 01, 2024	Jacob Johnson	Stifel Nicolaus	$315.00	$273.63	15.1%
Apr 23, 2024	Justin Bowers	Deutsche Bank	$270.00	$236.08	14.4%
Apr 17, 2024	Rajesh Kumar	HSBC	$280.00	$240.34	16.5%
Sep 27, 2023	Paul Knight	Loop Capital Markets	$300.00	$247.44	21.2%

Danaher Dividends

Explore Danaher's dividend history, including dividend yield, payout ratio, and historical payments.

Dividend Yield

0.46%

Dividend Payout Ratio

19.70%

Dividend Paid & Capex Coverage Ratio

3.10x

Danaher Dividend History

Dividend	Adjusted Dividend	Date	Record Date	Payment Date	Declaration Date
$0.27	$0.27	December 27, 2024	December 27, 2024	January 31, 2025	December 10, 2024
$0.27	$0.27	September 27, 2024	September 27, 2024	October 25, 2024	September 10, 2024
$0.27	$0.27	June 28, 2024	June 28, 2024	July 26, 2024	May 07, 2024
$0.27	$0.27	March 27, 2024	March 28, 2024	April 26, 2024	February 21, 2024
$0.24	$0.24	December 28, 2023	December 29, 2023	January 26, 2024	December 05, 2023
$0.27	$0.27	October 11, 2023	October 12, 2023	October 27, 2023	September 12, 2023
$0.27	$0.23936	June 29, 2023	June 30, 2023	July 28, 2023	May 09, 2023
$0.27	$0.23936	March 30, 2023	March 31, 2023	April 28, 2023	February 22, 2023
$0.25	$0.22163	December 29, 2022	December 30, 2022	January 27, 2023	December 06, 2022
$0.25	$0.22163	September 29, 2022	September 30, 2022	October 28, 2022	September 13, 2022
$0.25	$0.22163	June 23, 2022	June 24, 2022	July 29, 2022	May 10, 2022
$0.25	$0.22163	March 24, 2022	March 25, 2022	April 29, 2022	February 23, 2022
$0.21	$0.18617	December 29, 2021	December 30, 2021	January 28, 2022	December 07, 2021
$0.21	$0.18617	September 29, 2021	September 30, 2021	October 29, 2021	September 14, 2021
$0.21	$0.18617	June 24, 2021	June 25, 2021	July 30, 2021	May 05, 2021
$0.21	$0.18617	March 25, 2021	March 26, 2021	April 30, 2021	February 23, 2021
$0.18	$0.15957	December 24, 2020	December 28, 2020	January 29, 2021	December 08, 2020
$0.18	$0.15957	September 25, 2020	September 28, 2020	October 30, 2020	September 15, 2020
$0.18	$0.15957	June 25, 2020	June 26, 2020	July 31, 2020	May 05, 2020
$0.18	$0.15957	March 26, 2020	March 27, 2020	April 24, 2020	February 20, 2020

See full dividend history

Peers: Medical - Diagnostics & Research

This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.

Company	Market Cap	Price	EPS	P/E Ratio	P/B Ratio
Agilent Technologies, Inc. A	$42.33B	$148.38	$4.43	$29.42	$6.43
Illumina, Inc. ILMN	$18.06B	$113.88	$-7.69	$-17.37	$0.00
IDEXX Laboratories, Inc. IDXX	$38.11B	$465.47	$10.79	$38.33	$0.00
Waters Corporation WAT	$24.61B	$414.44	$10.87	$30.28	$16.91
Thermo Fisher Scientific Inc. TMO	$219.34B	$573.45	$16.58	$31.37	$0.00
Mettler-Toledo International Inc. MTD	$29.74B	$1409.35	$40.67	$30.09	$0.00
Charles River Laboratories International, Inc. CRL	$8.50B	$166.16	$9.27	$25.52	$3.37
Invitae Corporation NVTA	$5.44M	$0.02	$-13.18	$-0.14	$4.30
Guardant Health, Inc. GH	$5.54B	$44.83	$-4.28	$-6.32	$19.09
Revvity, Inc. RVTY	$14.44B	$118.62	$2.20	$50.56	$0.00